2 results
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
Approved WMOPending
The purpose of this study is to compare the good and bad effects of bermekimab to the good and bad effects of adalimumab and/or placebo. Adalimumab is a drug already used to treat moderate to severe hidradenitis suppurativa (HS).